Aurinia Pharmaceuticals (AUPH) Enterprise Value (2016 - 2026)

Aurinia Pharmaceuticals has reported Enterprise Value for 11 years, with the latest figure at -$378.8 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 21.06% year-over-year to -$378.8 million; the trailing twelve-month figure through Mar 2026 stood at -$378.8 million (down 21.06% YoY), and the FY2025 full-year result was -$398.0 million, down 11.02% from the prior year.
• Enterprise Value for Q1 2026 stood at -$378.8 million, up from -$398.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$312.9 million in Q1 2025, with the low at -$418.8 million in Q1 2022.
• Historically, Enterprise Value has averaged -$358.3 million across 5 years, with a median of -$351.8 million in 2025.
• The largest YoY upside for Enterprise Value was 16.45% in 2022 against a maximum downside of 31.51% in 2022.
• Aurinia Pharmaceuticals' Enterprise Value stood at -$389.4 million in 2022, then rose by 9.99% to -$350.5 million in 2023, then fell by 2.28% to -$358.5 million in 2024, then dropped by 11.02% to -$398.0 million in 2025, then increased by 4.83% to -$378.8 million in 2026.
• The last three Enterprise Value figures came in at -$378.8 million (Q1 2026), -$398.0 million (Q4 2025), and -$351.8 million (Q3 2025), per Business Quant data.